Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (JNJ) reported that TREMFYA met its primary and major secondary endpoints in the Phase 4 STAR axial psoriatic arthritis study. At Week 24, it met the primary endpoint for improvement versus placebo in BASDAI, a patient-reported disease activity score that includes spinal pain and stiffness. Major secondary endpoints showed reductions in axial symptoms measured by ASDAS-CRP and in sacroiliac-joint inflammation measured by MRI.
The randomized, double-blind, placebo-controlled study enrolled 411 biologic-naïve adults with active psoriatic arthritis and MRI-confirmed axial inflammation. Its 24-week placebo-controlled period is followed by 24 weeks of active treatment. The observed safety profile was consistent with TREMFYA’s established profile in psoriatic arthritis, with no new safety signals identified. Detailed efficacy and safety results, including MRI findings, are due at an upcoming scientific congress.
Johnson & Johnson (JNJ) reported five-year CARTITUDE-2 data showing 10 of 20 CARVYKTI-treated patients alive and progression-free without maintenance therapy. The Phase 2 cohort included patients with relapsed or refractory multiple myeloma who had received one to three prior lines of treatment. At a median follow-up of 60.7 months, the five-year overall survival rate was 69.2%, and median progression-free survival was 60.5 months.
Patients received one CARVYKTI infusion. At five years, three patients underwent bone-marrow testing for minimal residual disease, meaning cancer cells undetectable by the test used; all three tested negative at the deepest level measured. Testing was not required by the study protocol. Since the previous analysis, one patient developed acute myeloid leukemia, and two deaths occurred due to progressive disease and new cancer. No new CAR T-cell-related neurotoxicity was reported.
Johnson & Johnson (JNJ) reported new MajesTEC-3 analyses showing TECVAYLI plus DARZALEX FASPRO markedly improves outcomes in relapsed/refractory multiple myeloma.
Using a relative survival mixture cure model in patients with 1–3 prior lines of therapy, ~87% of those treated with the combination were estimated to have mortality risk and projected life expectancy similar to an age‑matched general population. Best‑fit modeling estimated an OS “cure fraction” of 86.6% versus 0% with pomalidomide- or bortezomib‑based standard of care and projected remaining life expectancy of 18.5 years versus 4.9 years.
A post hoc competing‑risk analysis showed a 90% reduction in disease‑progression risk at 36 months (8.7% vs 62.1% cumulative incidence) and 36‑month OS of 83.3% vs 65.0%, without a significant increase in non‑relapse mortality. MajesTEC-3 follow‑up is ongoing, and the company notes these long‑term projections remain model‑based.
DePuy Synthes (JNJ) will showcase next-generation trauma innovations at the 2026 Orthopaedic Trauma Association Annual Meeting in Nashville. The company is highlighting four new VOLT™ plating systems that expand its Variable Angle Optimized Locking Technology portfolio for fracture fixation across the ankle, knee and shoulder, designed using MOSAIC™ technology to improve implant fit across diverse anatomies.
DePuy Synthes is also presenting the MAXFRAME AUTOSTRUT™ with Bluetooth® Multi-Axial Correction System, now commercially available in the U.S. and described as combining automated device adjustments with real-time remote monitoring for complex limb reconstruction. A new VELYS™ Trauma AI-Assisted Surgery technology for intraoperative 3D guidance in fracture care is planned to launch in the U.S. in 2027, alongside an expanded soft tissue and biologics portfolio and demos of the SOURCEVIEW™ Analytics Platform.
Johnson & Johnson (JNJ) reported positive topline results from a pivotal Phase 3 trial of CAPLYTA (lumateperone) 42 mg once daily for acute manic episodes in adults with bipolar I disorder.
The randomized, double-blind Study 451 showed CAPLYTA achieved a statistically significant 4.8-point greater reduction in Young Mania Rating Scale (YMRS) total score versus placebo at Week 3 (effect size −0.69; p<.0001), with significant improvement observed as early as Day 3 and sustained through Week 3. Patients on CAPLYTA also had greater improvement in overall illness severity on the Clinical Global Impression–Severity scale (least-squares mean difference −0.5; p<.0001) and roughly double the clinical response rate, defined as ≥50% YMRS reduction, compared with placebo (45.8% vs. 20.9%; p<.0001). CAPLYTA’s safety and tolerability were consistent with its established profile, with low discontinuation rates; common treatment-related adverse events ≥5% and at least twice placebo were dry mouth and nausea (each 7.9% vs. 3.4% and 2.3%, respectively). CAPLYTA is not approved for treating manic episodes in bipolar I disorder, and a second Phase 3 mania study has completed enrollment with data analysis ongoing.
Johnson & Johnson (JNJ) reported new Phase 2b COPERNICUS data on subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE (lazertinib) with prophylactic strategies in previously untreated EGFR-mutated advanced non-small cell lung cancer.
In 214 U.S. patients, treated with once-every-four-weeks dosing and prophylaxis for venous thromboembolism (VTE) and skin toxicity, most adverse events were Grade 1–2 at a median 8.3‑month follow-up, with no new safety signals. Rash occurred in 25% of patients, administration-related reactions and VTE each in 3%, and 8% discontinued due to adverse events; fewer than 1% discontinued for rash or VTE, and none for administration-related reactions. These rates were numerically lower than with intravenous RYBREVANT plus LAZCLUZE in the MARIPOSA Phase 3 study, where rash, administration-related reactions and VTE in the first four months were 55%, 55% and 23%, respectively. MARIPOSA previously showed a statistically significant overall survival benefit versus osimertinib (HR 0.75; P=0.005).
Johnson & Johnson (JNJ) reported final overall survival results from the Phase 3 PAPILLON study of first-line IV RYBREVANT (amivantamab-vmjw) plus carboplatin-pemetrexed versus chemotherapy alone in advanced NSCLC with EGFR exon 20 insertion mutations.
The combination achieved a median overall survival of 34.3 months versus 27.9 months with chemotherapy alone, despite 76 percent of eligible chemotherapy patients crossing over to second-line RYBREVANT. This is described as the longest reported median OS in this population and nearly double historical medians. A prespecified crossover-adjusted analysis showed a 43 percent reduction in risk of death (HR 0.57; 95% CI 0.39–0.82; nominal P=0.003). Progression-free survival through second progression (PFS2) was 28.3 versus 17.5 months (HR 0.59; nominal P<0.0001). Twelve percent of patients remained on first-line therapy at cutoff, and patient-reported outcomes favored the combination. Safety was consistent with prior experience, with no new signals and common treatment-related events including paronychia (60%), neutropenia (60%) and rash (58%).
Johnson & Johnson (JNJ) received CE Marking for ACUVUE OASYS MAX 2-Week, a new reusable contact lens using MAX technologies designed to provide comfort and visual clarity through the full 14-day wear cycle. The lens combines Eye-Inspired Designs with an OptiBlue Light Filter that filters at least 60% of blue-violet light, TearStable Technology to lock in moisture, and Class 1 UV blocking in each lens.
The product will launch via a phased rollout starting in select European markets in late 2026, with broader expansion planned across 2027 and 2028, subject to local regulatory approvals and market readiness. ACUVUE OASYS MAX 2-Week is not approved by the U.S. FDA and is not available for sale in the United States.
Johnson & Johnson (JNJ) will present 24 abstracts with new clinical and real‑world neuropsychiatry data at the 2026 Psych Congress Annual Meeting in New Orleans from September 15‑19.
Highlights include first presentation of pivotal Phase 3 data for CAPLYTA (lumateperone) in adults with bipolar I mania, plus additional CAPLYTA data in bipolar depression and major depressive disorder. Further presentations cover SPRAVATO (esketamine) analyses focused on anhedonia, schizophrenia long‑acting injectable real‑world outcomes, and Phase 3 and real‑world data for investigational agent seltorexant in MDD with insomnia symptoms. Johnson & Johnson states these efforts reflect a focus on complex, high‑burden mood and psychotic disorders.
Johnson & Johnson (JNJ) will present at the Deutsche Bank 2026 Healthcare Summit on Thursday, September 17, 2026. Company management will join a Fireside Chat at 12:00 p.m. Eastern Time. A live audio webcast and later archived replay will be available via the Johnson & Johnson Investor Relations website.